No business profile yet.
Size Excelsior Medical (4104.TW) is a Taiwan Health Care company (Medical Distributors) with a market value of $404M, the 513th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$71.20 on 18 Nov 2026.
Performance Over six months the shares gained 4.5%, against -5.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 11.1% over the last twelve months (peer median +2.9%); the operating margin is 7.8% (peer median 1.9%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 1.1× (7th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.7 points below its cost of capital (5.0% WACC).
Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$9.75B | NT$8.79B | NT$8.54B | NT$8.24B | NT$7.19B |
| Revenue growth | — | +3% | +4% | +15% | — |
| Gross profit | NT$2.02B | NT$1.80B | NT$1.72B | NT$1.62B | NT$1.46B |
| EBITDA | NT$1.12B | NT$1.04B | NT$1.05B | NT$969M | NT$829M |
| Net income | NT$905M | NT$806M | NT$771M | NT$747M | NT$667M |
| Free cash flow | NT$1.57B | -NT$1.27B | NT$2.65B | NT$178M | NT$718M |
| Capital expenditure | NT$133M | NT$83.0M | NT$121M | NT$143M | NT$173M |
| Total debt | NT$2.13B | NT$2.16B | NT$1.43B | NT$1.44B | NT$808M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4104.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | -4.1% | 10th highest of 21 |
| 6-month return | +4.5% | -5.6% | 6th highest of 21 |
| Distance from 52-week high | -15.4% | -22.4% | 7th highest of 21 |
| Revenue growth (TTM) | +11.1% | +2.9% | 5th highest of 21 |
| Operating margin | 7.8% | 1.9% | 5th highest of 21 |
| EV / Sales | 1.4× | 1.1× | 7th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -1.2% | 4.7% | 6th least demanding of 16 |
| Growth delivered (Del g) | +5.7% | +6.0% | 8th lowest of 16 |
| Hurdle (Req g minus delivered) | -6.9 pp | -5.0 pp | 6th least demanding of 16 |
| ROIC minus cost of capital | -0.7 pp | -0.2 pp | 10th lowest of 21 |
| EV / EBITDA | 12.5× | 7.3× | most expensive of 4 |
| Net debt / EBITDA | -2.4× | 1.5× | 2nd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Excelsior Medical 4104.TW | Taiwan | $404M | +5% | +11% | 8% | 1.4× | -1.2% | +5.7% |
| Vital KSK 3151.T | Japan | $399M | -1% | +3% | 0% | 0.1× | 4.7% | +2.6% |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | 0.6× | 58.3% | -7.8% |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | 288.8× | n/a | n/a |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | 4.3× | n/a | n/a |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | 1.1× | 21.1% | -18.1% |
| Shanghai Universal Biotech 301166.SZ | China | $337M | -15% | +15% | -4% | 1.0× | n/a | n/a |
| Nagaileben 7447.T | Japan | $319M | 0% | +1% | 21% | 1.6× | -12.7% | -0.4% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | 0.7× | 13.1% | +7.5% |
| Rongfeng 000668.SZ | China | $297M | -32% | +61% | 14% | 4.8× | 9.6% | +30.0% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | 2.1× | -1.6% | +1.0% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 0.1× | -6.2% | +3.8% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 0.3× | 5.3% | +8.1% |
| Shanghai Haohai Biological Technology 688366.SS | China | $878M | -24% | -9% | -2% | 1.8× | 16.9% | +13.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 1.2× | 24.7% | +29.9% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |